RxDoctor Payments Data

Madhu Mendiratta, MD

Psychiatry · Southfield, MINPI 1467447441

Payments from drug & device makers

$2,546in general payments, 2019–2025

Across 138 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$582
  • Lundbeck LLC$502
  • AbbVie$310
  • Takeda Pharmaceuticals U.S.A., Inc.$222
  • Axsome Therapeutics, Inc.$175
  • Sunovion Pharmaceuticals Inc.$147
  • plus $607 from 8 others

What the payments were for

  • Food & beverage$2,546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,546 in reported general payments places this provider in the 85th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$129,214
Medicare patients
101
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole103$149,894
VraylarCariprazine Hcl50$70,444
Invega SustennaPaliperidone Palmitate22$60,279
TrintellixVortioxetine Hydrobromide75$35,811
LybalviOlanzapine/Samidorphan Malate16$24,411
AuvelityDextromethorphan Hbr/Bupropion16$14,965
Lurasidone Hcl43$11,410
Aripiprazole OdtAripiprazole31$7,841
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl82$6,475
Aripiprazole182$4,681
Asenapine Maleate12$3,763
Bupropion XlBupropion Hcl158$2,005
Venlafaxine Hcl ErVenlafaxine Hcl70$1,935
Quetiapine Fumarate117$1,850
Amitriptyline Hcl156$1,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$582$149,894103 claims
AbbVieVraylar$310$70,44450 claims
Johnson & JohnsonInvega Sustenna$107$60,27922 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$222$35,81175 claims
Alkermes, Inc.Lybalvi$122$24,41116 claims
Axsome Therapeutics, Inc.Auvelity$175$14,96516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →